CLABSI Study – A New Pathway to Reduce CLABSI in Hospitals
Central venous catheters (CVCs) are used for the administration of intravenous fluids, blood products, medications, and parenteral nutrition. They also provide access for hemodialysis and other forms of long-term treatment, such as chemotherapy.
Widespread and essential, CVCs are also a frequent cause of healthcare-associated bloodstream infections. It is estimated that 250,000 cases of central line–associated bloodstream infections (CLABSIs) occur in the U.S. every year. According to the CDC, CLABSIs are associated with a mortality rate of 12–25%. Each CLABSI episode costs approximately $22,000, which includes the burdens of additional diagnosis and treatment, and prolonged hospital stays.
CLABSI rates can be reduced, if not eliminated, by adherence to evidence-based protocols. National CLABSI rates have shown a 50% drop between 2008 and 2016. Several hospitals throughout the U.S. have managed to maintain a 0% CLABSI rate for months, even years, by following these protocols.
So why does CLABSI still happen? A major US health system employed the Amplifire training tool to acquire data on what its nurses know and don’t know about these protocols for managing CVCs, and to find and fix any misinformation the nurses held.